Medivation Inc (MDVN)

MDVN (NASDAQ:Drugs)
$77.83
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | MDVN Avg Daily Volume: 968,600
Last Update: 07/23/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 21.95%
Open: $0.00
Previous Close: $77.83
52 Week Range: $48.15 - $88.20
Oustanding Shares: 76,523,977
Market Cap: 5,570,945,526
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 9 10
Moderate Buy 0 0 0 0
Hold 4 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.80 1.80 1.86 1.88
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -192.08
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
-192.08 0.00 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
29.63% 39.71% 615.35%
GROWTH 12 Mo 3 Yr CAGR
Revenue 50.20 3.37 0.63
Net Income 0.00 0.25 0.00
EPS 0.00 0.14 0.00
Earnings for MDVN:
EBITDA -0.02B
Revenue 0.27B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $0.25 $0.48 $1.37 $2.93
Number of Analysts 7 7 8 8
High Estimate $0.34 $0.95 $1.68 $4.57
Low Estimate $0.20 $-0.07 $1.11 $1.73
Prior Year $-0.07 $-0.18 $-0.57 $1.37
Growth Rate (Year over Year) 463.27% 368.25% 339.47% 114.38%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bearish
Mar 03, 2014 | 7:49 AM EST
MDVN lowered its numbers, UBS said. Driven by disappointing Xtandi guidance. $85 price target and Buy rating, 
Bearish
Feb 03, 2014 | 7:36 AM EST
MDVN was downgraded from Buy to Hold, Needham said. Valuation call.   
Bullish
Jan 29, 2014 | 7:31 AM EST
MDVN raised its price target and estimates through 2015, UBS said. Better-than-expected full PREVAIL data, appearing favorably vs Zytig...
Bullish
Jul 17, 2013 | 7:57 AM EDT
MDVN was upgraded to Buy from Neutral and given a $74 price target, said UBS. The upgrade comes ahead of the ph3 PREVAIL study.
Bullish
Mar 04, 2013 | 7:09 AM EST
MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.   ...
Update
Dec 19, 2012 | 8:44 AM EST
MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expecta...
Bullish
Nov 12, 2012 | 8:09 AM EST
Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.

Adam Feuerstein, Sr. Columnist for TheStreet, says biotech earnings are the next big things to watch in biotech.

Bullish
Oct 03, 2012 | 7:35 AM EDT
Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
Motivated CEOs, innovative products and smart deals count more than macro events.

Columnist Conversations

Lang:
After two weeks off we are BACK in gear with a fresh new webinar, after the close today. Sign up below, alway...
Lang:
Amazing growth metrics for FB last night has this one perking toward a new all time high this am. Back on Jun...
To go along with my column this morning how there is no giddiness in the market, this week's AAII bulls are th...
The semiconductor sector performed poorly today with the Market Vectors Semiconductor (SMH) fund down over 2% ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.